A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301)
TYR300-101
Phase 2 other active
Quick answer
A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301) for Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations is a Phase 2 program (other) at Tyra Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Tyra Biosciences
- Indication
- Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations
- Phase
- Phase 2
- Modality
- other
- Status
- active